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CLINICAL UTILITY GENE CARD
Clinical utility gene card for: WAGR syndrome
Carol Clericuzio*,1, Melanie Hingorani2, John A Crolla3 and Veronica van Heyningen4 and Alain Verloes5
European Journal of Human Genetics (2011) 19, doi:10.1038/ejhg.2010.220; published online 12 January 2011
1. DISEASE CHARACTERISTICS
1.1 Name of the disease (synonyms)
WAGR syndrome; Wilms tumor, aniridia, genitourinary anomalies
and mental retardation syndrome; chromosome 11p13 deletion
syndrome.
1.2 OMIM# of the disease
194072.
1.3 Name of the analyzed genes or DNA/chromosome segments
WT1, PAX6.
1.4 OMIM# of the gene(s)
607102 (WT1), 607108 (PAX6).
1.5 Mutational spectrum
Breakpoints differ in individual cases, but the minimum deletion
involves both PAX6 and WT1, which are B700 kb apart in the distal
half of band 11p13.
1.6 Analytical methods
FISH, array CGH, MLPA, high-resolution cytogenetics may identify
larger deletions and chromosomal rearrangements. Expert advice
should be sought if an etiology is not identified.1,2
1.7 Analytical validation
Analyze known non-deleted and deleted cases in parallel as controls to
show that reagents used for FISH, array CGH andMLPA are working well.
1.8 Estimated frequency of the disease
(Incidence at birth (‘birth prevalence’) or population prevalence):
Rare, with only a few hundred cases reported.
1.9 If applicable, prevalence in the ethnic group of the investigated
person
Not applicable.
1.10 Diagnostic setting
2. TEST CHARACTERISTICS
2.1 Analytical sensitivity
(proportion of positive tests if the genotype is present)
Essentially 100% with appropriate FISH probes, MLPA or array CGH.
Cytogenetic analysis is less sensitive and, if normal, one of the above
methods must be used. Very rarely mosaic sub-microscopic deletions
will reduce the analytical sensitivity of MLPA and array CGH but not
the use of appropriate FISH probes.
2.2 Analytical specificity
(proportion of negative tests if the genotype is not present)
Essentially 100% with appropriate FISH probes, MLPA or array CGH.
2.3 Clinical sensitivity
(proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as
age or family history. In such cases a general statement should be
given, even if a quantification can only be made case by case.
Nearly 100% if sporadic aniridia and Wilms tumor, male genitour-
inary abnormalities or significant nephropathy is present. If sporadic
aniridia alone is present (eg, a newborn female), then 10–30% have
WAGR syndrome (data limited by small numbers).3
2.4 Clinical specificity
(proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as
age or family history. In such cases a general statement should
be given, even if a quantification can only be made case by case.
It is worthwhile pointing out that other 11p13 deletions that include
WT1 but do not involve PAX6 can occur. Therefore, for patients
without aniridia but for whom WT1 deletion is suspected
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(eg, a patient with Wilms tumor, genitourinary abnormalities and
cognitive impairment), genetic testing for 11p13 deletion is recom-
mended.
Essentially 100% if aniridia is not present.
2.5 Positive clinical predictive value
(lifetime risk to develop the disease if the test is positive)
Essentially 100% for aniridia (which is congenital), other features due
to WT1 gene deletion are variable. In all, 42.5–77% have been shown
to develop Wilms tumor depending on the deletion size. End-stage
renal disease develops in 47% of WAGR patients with Wilms tumor
by 20 years after diagnosis and also occurs in those without
WT. Individuals with XY genotype and intra-abdominal gonads
have a high risk of gonadoblastoma and should undergo gonadect-
omy. XY individuals with descended testes must undergo regular
examination for testicular tumors. Individuals with XX genotype
have also developed gonadoblastoma and should be screened by
imaging.4,5
2.6 Negative clinical predictive value
(probability not to develop the disease if the test is negative).
Assume an increased risk based on family history for a non-affected
person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested:
Essentially 100% if no aniridia.
Index case in that family had not been tested:
Essentially 100% if no aniridia.
3. CLINICAL UTILITY
3.1 (Differential) diagnosis: the tested person is clinically affected
(To be answered if in 1.10 ‘A’ was marked)
3.1.1 Can a diagnosis be made other than through a genetic test?
3.1.2 Describe the burden of alternative diagnostic methods to the
patient.
Not applicable.
3.1.3 How is the cost effectiveness of alternative diagnostic methods
to be judged?
Not applicable.
3.1.4 Will disease management be influenced by the result of a
genetic test?
3.2 Predictive setting: the tested person is clinically unaffected but
carries an increased risk based on family history
(To be answered if in 1.10 ‘B’ was marked)
3.2.1 Will the result of a genetic test influence lifestyle and
prevention?
If the test result is positive (please describe)
See 3.1.4 for management if test result is positive.
If the test result is negative (please describe)
If test result is negative, eg, a sporadic aniridia patient does not have
a WT1 deletion, then monitoring for genitourinary complications,
including Wilms tumor, is not warranted.
3.2.2 Which options in view of lifestyle and prevention does a person
at risk have if no genetic test has been done (please describe)?
An individual with sporadic aniridia should undergo screening for
Wilms tumor by renal ultrasound and urinalysis every 3 months until
6 years and daily caretaker abdominal examination. Renal disease
should be screened for by annual blood pressure and urinalysis for
proteinuria beginning in early adolescence and through adulthood.
There is also risk for gonadoblastoma (see 2.5 above).8
3.3 Genetic risk assessment in the family members of a diseased
person
(To be answered if in 1.10 ‘C’ was marked)
There are rare instances of familial recurrence of WAGR syndrome
due to inherited chromosomal rearrangements or submicroscopic
WAGR deletions. Parents and all at-risk relatives (determined
by pedigree analysis) should be evaluated for a WAGR-associated
chromosomal rearrangement or sub-microscopic deletion.9,10
3.3.1 Does the result of a genetic test resolve the genetic situation
in that family?
Yes.
3.3.2 Can a genetic test in the index patient save genetic or other tests
in family members?
Yes.
No 2 (continue with 3.1.4)
Yes &
Clinically &
Imaging &
Endoscopy &
Biochemistry &
Electrophysiology &
Other (please describe):
Prognosis
(please describe)
Good for Wilms tumor treatment. Individuals with
end-stage renal disease may require transplantation.
Cognitive deficits are lifelong. Visual acuity is reduced
significantly in most patients and further ocular
complications may be severe, including cataract,
glaucoma, and corneal opacification/vascularization.
Management
(please describe)
Depends on specific manifestations. Aniridia should
be managed by an expert ophthalmologist. Supportive
measures for the visually impaired are required and
ophthalmologists will monitor to identify and treat
later-onset corneal disease, glaucoma and cataract.
Early identification of nephropathy allows referral for
expert management. Wilms tumor may require surgery,
chemotherapy and occasionally radiotherapy.
Gonadoblastoma requires surgical treatment (see 2.5
above). Obesity and its complications are common.
Special education and behavioral management
(including interventions for autism) are frequently required
for cognitive impairment.6,7
No &
Yes 2
Therapy
(please describe)
Ultrasound screening for Wilms tumor allows for
early diagnosis and therefore decreased treatment
toxicity. See other management below.
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3.3.3 Does a positive genetic test result in the index patient enable a
predictive test in a family member?
Yes, for prenatal diagnosis in the event of a familial chromosomal
rearrangement or inherited sub-microscopic deletion.
3.4 Prenatal diagnosis
(To be answered if in 1.10 ‘D’ was marked)
An individual with WAGR syndrome has B50% chance of
passing on the deleted chromosome to the offspring. Prenatal testing
for the parental deletion or chromosome rearrangement should be
offered.
3.4.1 Does a positive genetic test result in the index patient enable a
prenatal diagnosis?
Yes.
4. IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate
medical consequences. Is there any evidence that a genetic test is
nevertheless useful for the patient or his/her relatives? (Please
describe).
Yes. In addition to the value of understanding the cause and
recurrence risk of the disorder, many families have benefited greatly
from joining the International WAGR Syndrome Association support
group (http://www.wagr.org) and meeting other families. This support
group has been instrumental in gathering data about the natural
history of WAGR syndrome and stimulating research.
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